Skip to content

NASARR

Active Private limited companyfounded 2014active for 12 yearsLivornostraat 18 +, 1000 BrusselsKBO/BCE: BE 0550.921.891

Lifetime

11 annual accounts with figures on one time axis
peak of €228,759 in 2024
€226,160▼ 1.1%
lowest -€58,247 in 2017
€165,922▼ 0.9%
peak of €212,544 in 2024
€38,799▼ 81.7%
€260,840▲ 13×
Board1 name since 2014
1 director
Documentsfilings and deeds
29-01-20262 days before the deadline
2025micro format
Dividend €339,667Equity from €212,544 to €38,799Debts from €20,057 to €260,840

Key points

from the 2025 annual accounts

Equity

€38,799 from €212,544 in 2024

Equity fell by 82% in 1 year.

Turnover

≈ €420,000 estimated

The micro format states no turnover.

Debts

€260,840 87% of the balance sheet
Suppliers 0%Taxes and wages 22%Other 78%

Liquidity

1.08 was 10.53 in 2024

Short-term debts rose from €20,057 to €260,840.

Filings

11 annual accounts since 2015
deadline201520202025

The 2016 accounts came 28 days late. The other nine of the last ten were filed on time.

Position in the sector

12.9%

Lower solvency than 84% of companies in human health. Sector median 63.0% · 21,336 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 5,052 companies had the same profile as NASARR has now. Each dot stands for 13 companies, two years later.

95.9%
were still trading
2.4%
stopped another way
1.6%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 10 to 30%
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,760 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 5,052 companies, not a prediction for NASARR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 21-12-2023
  • 186 sharesdeed of 29-04-2014
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0550921891
Registered office moved to Brussels The registered office moved to Rue de Livourne 18+ appartement B5, 1000 Bruxelles · changes role from manager to director · General meeting of 21-12-2023 · Gazette deed
New establishment in Brussels Livornostraat 18
Incorporation Founding capital of €18,600, 186 shares, €12,400 paid up · Founded by (comparant) · appointed as manager · published on 29-04-2014 · Gazette deed
All 23 events

Comparable companies

same main activity, similar in size and age
Company
NASARR Brussels €299,639 €226,160 12.9% -
BLEUGIMED Tournai €307,223 €226,237 7.1% -
Docteur A. CHACHATI Liège €293,987 €230,914 7.2% -
DOKTER FLEUR DE METSENAERE, GYNAECOLOGIE Maldegem €314,170 €219,629 86.3% -
SPINECO, Docteur Nicaise Namur €311,930 €238,190 29.3% -
DR. GREET PEETERS Kapellen €271,411 €229,347 86.3% -
Plastische Chirurgie Dr. Marek Klinkenberg Eupen €308,287 €208,794 6.6% -

These companies have the same main activity as NASARR: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €271,000 and €314,000, founded between 2013 and 2014.

Official details

Source: KBO
Status
Active since 25-04-2014Normal situation
Activity
Specialist medical practiceNACE 86220
Establishment units
2.231.139.2631000 Brussels, since 25-04-2014
2.357.274.9941000 Brussels, since 21-12-2023
Financial year end
30 June
Peppol
Reachable since 30-12-2025
Company details

Annual accounts to 30-06-2025

€299,639▲ 28.8%
Filing
Filed on 29-01-2026, 2 days before the end of the filing period
Financials

Insights on NASARR

NASARR files the micro format. That format states no turnover. The gross margin rose from €161,082 in 2015 to €226,160 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about NASARR

What is the company number of NASARR?
The company number of NASARR is 0550.921.891. The VAT number is the same number with BE in front: BE 0550.921.891.
Where is NASARR based?
The registered office is at Livornostraat 18 +, 1000 Brussels.Company details
What does NASARR do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of NASARR?
NASARR is a private limited company (BV).
When was NASARR founded?
NASARR was founded on 25-04-2014.
Is NASARR still active?
Yes, NASARR is an active enterprise in the KBO register.
What is the turnover of NASARR?
The turnover in financial year 2025 is ≈ €420,000. This figure is estimated from the gross margin of €226,160 and 40 comparable companies (NACE 86220). It probably lies between €360,000 and €560,000.Financials
Is NASARR profitable?
In financial year 2025, NASARR made a profit of €165,922.
Where can I find the annual accounts of NASARR?
NASARR filed 11 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of NASARR due?
NASARR must file the annual accounts for financial year 2026 by 31-01-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.